Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Artelo Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ARTL
Nasdaq
8731
https://artelobio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Artelo Biosciences Inc
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
- Apr 23rd, 2024 12:30 pm
Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
- Apr 22nd, 2024 12:30 pm
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
- Mar 25th, 2024 12:00 pm
Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
- Mar 12th, 2024 1:15 pm
Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th
- Feb 15th, 2024 2:00 pm
Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
- Jan 23rd, 2024 1:30 pm
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
- Jan 8th, 2024 1:30 pm
Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
- Dec 5th, 2023 1:30 pm
Artelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
- Nov 30th, 2023 2:00 pm
Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 13th, 2023 1:00 pm
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers
- Nov 9th, 2023 2:00 pm
Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023
- Nov 2nd, 2023 12:30 pm
Principal Investigator of Artelo’s CAReS Trial to Participate in Medical Expert Webinar Hosted by H.C. Wainwright to Discuss Current Development Strategies for Cancer-Related Anorexia and Cachexia
- Oct 4th, 2023 12:30 pm
Artelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th
- Sep 13th, 2023 12:30 pm
Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12
- Sep 7th, 2023 12:00 pm
Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th
- Sep 6th, 2023 1:00 pm
Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th
- Sep 5th, 2023 1:00 pm
Artelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
- Aug 10th, 2023 12:00 pm
Artelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023
- Jul 19th, 2023 1:00 pm
Artelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11
- Jul 10th, 2023 12:30 pm
Scroll